Dignitana AB is a Swedish medical technology company listed on the NASDAQ OMX First North stock exchange in Stockholm. The company is currently focusing on a widespread market launch of the DigniCap® scalp cooling system – a product that counteracts chemotherapy-related hair loss in breast cancer patients and may significantly contribute to improving patient well being and quality of life.
Dignitana develops a patented scalp cooling system, DigniCap®, that reduces chemotherapy-induced hair loss. Dignitana’s patented DigniCap® system has proven its safety and efficacy in clinical studies.
Dignitana, Inc. is a wholly owned subsidiary of Dignitana AB and is responsible for North American distribution and support for the DigniCap® scalp cooling system.
About the DigniCap® scalp cooling system. Dignitana’s core product – DigniCap® – is a patented scalp cooling system that offers women with breast cancer the ability to keep their hair during chemotherapy. DigniCap® provides continuous cooling with high efficacy, safety and acceptable patient comfort.
Find out where the DigniCap® scalp cooling system is currently available.